Details of the Drug Combination

General Information of Drug Combination (ID: DCA9UL7)

• Drug Combination Name: Hepzato + Aminolevulinic Acid Hydrochloride
• Indication: Carcinoma; Status: Investigative [1]
• Component Drugs:
  Hepzato (DM2AZPP): N.A.
  Aminolevulinic Acid Hydrochloride (DMWNHPC): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: MCF7
  Zero Interaction Potency (ZIP) Score: 0.27
  Bliss Independence Score: 5.2
  Loewe Additivity Score: 0.22
  LHighest Single Agent (HSA) Score: 4.11

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Hepzato

Disease Entry	ICD 11	Status	REF
Uveal Melanoma	2D0Y	Phase 3	[2]

Indication(s) of Aminolevulinic Acid Hydrochloride

Disease Entry	ICD 11	Status	REF
Actinic keratosis	EK90.0	Approved	[3]

Aminolevulinic Acid Hydrochloride Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Protoporphyrinogen oxidase (PPOX)	TTNFMS9	PPOX_HUMAN	Modulator	[4]

References

• [1] Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
• [2] ClinicalTrials.gov (NCT05022901) An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma. U.S.National Institutes of Health.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.